Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Lyon sold 10,000 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $113.49, for a total value of $1,134,900.00. Following the transaction, the insider owned 5,683 shares of the company’s stock, valued at approximately $644,963.67. This trade represents a 63.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Joseph Douglas Lyon also recently made the following trade(s):
- On Monday, August 3rd, Joseph Lyon sold 1,540 shares of Corcept Therapeutics stock. The shares were sold at an average price of $114.16, for a total value of $175,806.40.
Corcept Therapeutics Price Performance
CORT stock opened at $111.81 on Thursday. The stock has a market capitalization of $12.09 billion, a P/E ratio of 266.22 and a beta of 0.45. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $126.38. The business has a 50-day moving average of $107.76 and a 200-day moving average of $74.40.
Hedge Funds Weigh In On Corcept Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Corcept Therapeutics in the second quarter valued at about $1,080,964,000. First Trust Advisors LP lifted its stake in shares of Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after buying an additional 1,480,059 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after buying an additional 734,646 shares during the period. Norges Bank bought a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $24,213,000. Finally, Bank of New York Mellon Corp acquired a new position in Corcept Therapeutics in the 2nd quarter valued at about $49,185,000. 93.61% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently commented on CORT. Weiss Ratings cut shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Truist Financial started coverage on shares of Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price target on the stock. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. HC Wainwright increased their price objective on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a report on Monday, July 27th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $138.17.
Check Out Our Latest Research Report on CORT
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.
Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.
Featured Articles
- Five stocks we like better than Corcept Therapeutics
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.